Alnylam Seals $330M RNAi IP Deal, $42.5M Investment with Roche | GenomeWeb
NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals said yesterday that it has closed its previously announced strategic alliance with Roche under which Roche agreed to license an Alnylam RNAi therapeutic technology platform and certain intellectual property, acquire one of Alnylam’s labs, and work with the firm on drug-discovery projects.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.